Cell Therapeutics, Inc. Announces Closing of Registered Offering of $30 Million of Preferred Stock and Warrants
22 8월 2009 - 5:40AM
PR Newswire (US)
SEATTLE, Aug. 21 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
(Nasdaq and MTA: CTIC) (the "Company") today announced the closing
of its previously announced sale of $30 million of shares of its
Series 2 Preferred Stock and warrants to purchase shares of its
common stock in a registered offering to a single institutional
investor. The investor has elected to convert all of its shares of
Series 2 Preferred Stock and to receive the 18,853,103 shares of
the Company's common stock issuable upon such conversion at the
closing. The Company received approximately $28.2 million in net
proceeds from the offering, after deducting placement agent fees
and estimated offering expenses. In connection with the offering,
the investor received warrants to purchase up to 4,713,276 shares
of common stock. The warrants have an exercise price of $1.70 per
warrant share, for total potential additional proceeds to the
Company of approximately $8.0 million upon exercise of the
warrants. The warrants are exercisable immediately upon their date
of issuance and will expire nine months thereafter. Rodman &
Renshaw, LLC, a wholly-owned subsidiary of Rodman & Renshaw
Capital Group, Inc. (NASDAQ:RODM), acted as the exclusive placement
agent for the offering. A shelf registration statement relating to
the shares of Series 2 Preferred Stock and warrants issued in the
offering (and the shares of common stock issuable upon conversion
of the Series 2 Preferred Stock and exercise of the warrants) has
been filed with the Securities and Exchange Commission (the "SEC").
The shelf registration statement was automatically effective upon
filing with the SEC. A prospectus supplement relating to the
offering has also been filed with the SEC. Copies of the prospectus
supplement and accompanying prospectus may be obtained directly
from the Company by contacting the Company at the following
address: Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite
400, Seattle, Washington 98119. This announcement is neither an
offer to sell nor a solicitation of an offer to buy any of our
shares of Series 2 Preferred Stock or warrants. No offer,
solicitation or sale will be made in any jurisdiction in which such
offer, solicitation or sale is unlawful. This press release
includes forward-looking statements that involve a number of risks
and uncertainties, the outcome of which could materially and/or
adversely affect actual future results and the trading prices of
the Company's securities. The risks and uncertainties include the
risk that the investors might not exercise their warrants, the
Company might not be able to continue to raise additional capital
as needed to fund its operations, the Company's intentions
regarding the use of proceeds, and other risk factors listed or
described from time to time in the Company's filings with the SEC,
including, without limitation, its most recent filings on Forms
10-K, 10-Q and 8-K. Except as required by law, the Company does not
intend to update any of the statements in this press release upon
further developments. Media Contact: Dan Eramian T: 206.272.4343 C:
206.854.1200 E: http://www.celltherapeutics.com/press_room
Investors Contact: Ed Bell T: 206.272.4345 Lindsey Jesch Logan T:
206.272.4347 F: 206.272.4434 E:
http://www.celltherapeutics.com/investors DATASOURCE: Cell
Therapeutics, Inc. CONTACT: Media, Dan Eramian, +1-206-272-4343,
Cell, +1-206-854-1200, , or Investors, Ed Bell, +1-206-272-4345, or
Lindsey Jesch Logan, +1-206-272-4347, Fax, +1-206-272-4434, , all
of Cell Therapeutics, Inc. Web Site:
http://www.celltherapeutics.com/
Copyright